Baxter International, Inc. Presents ADVATE Data on Prophylaxis Management and Efficacy for Hemophilia A Patients

Published: Jul 08, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

AMSTERDAM--(BUSINESS WIRE)--Baxter International Inc. (NYSE: BAX) today announced data featuring ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method], a leading recombinant treatment available worldwide, during the 24th Annual Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Amsterdam, The Netherlands. The first study identifies a correlation between peak levels of factor VIII (FVIII) in the body and the efficacy of treatment, indicating that frequency of peaks may be important when choosing hemophilia treatments. A second presentation reinforces that for both hemophilia patients and parents, efficacy through reduction in bleeds considerably outweighs infusion convenience as the primary treatment priority.

Help employers find you! Check out all the jobs and post your resume.

Back to news